Table 3.
Categorization of albuminuria and median concentrations in three RCTs that recruited patients with CKD
| CREDENCE | DAPA-CKD | SCORED | |
|---|---|---|---|
| (n = 4401; | (n = 4304; | (n = 10 584; | |
| UACR | Canagliflozin) | Dapagliflozin) | Sotagliflozin) |
| Concentration in the placebo group (mg/g), median (IQR) | 923 (459–1794) | 934 (482–1868) | 74 (18–486) |
| Concentration in the SGLT2i group (mg/g), median (IQR) | 931 (473–1868) | 965 (472–1903) | 75 (17–477) |
| A1 (<30 mg/g), n (%) | 31 (0.7) | NA | 3709 (35.0) |
| A2 (30–300 mg/g), n (%) | 496 (11.3) | NA | 3589 (23.9) |
| A3 (>300 mg/g), n (%) | 3874 (88.0) | NA | 3286 (31.0) |
| UACR >1000 mg/g, n (%) | 2053 (46.6) | 2079 (48.3) | NA |
IQR, interquartile range; UACR, urinary albumin-to-creatinine ratio; NA, not available.